Strides Pharma Science Limited has informed the Exchange about Business Responsibility and Sustainability Report for FY 2025.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has filed its annual Business Responsibility & Sustainability Report (BRSR) for FY 2024-25 with the stock exchanges, as required under SEBI LODR regulations. The company is a 100% export-oriented pharmaceutical manufacturer with standalone turnover of ₹21,856.11 million and net worth of ₹27,478.84 million; exports contributed 95.22% of revenue, and products are sold in 106 countries. The company has 2,245 permanent employees and 1,056 permanent workers across 5 national and 3 international plants. Key highlights include 25% women representation on the board, ~62% independent directors (effective April 5, 2025), no Class I product recalls during the year, and an independent EcoVadis assessment. The company disclosed a ₹1.51 Crore compounding fee paid to the RBI in September 2024 for a past ESOP/R&D expenditure compliance matter, which is now closed.
This is a routine annual regulatory compliance filing and is unlikely to move the stock on its own. However, it does disclose the closure of the RBI compounding matter, improvement in board diversity, and progress on sustainability commitments (including a net-zero 2045 target for the UK subsidiary), which are useful signals for ESG-focused investors.